New hope for rare brain tumor? drug trial targets recurrent craniopharyngioma
NCT ID NCT06970145
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests a drug called anlotinib in 57 adults with a rare brain tumor (craniopharyngioma) that has returned after surgery. The main goal is to see if the drug can shrink the tumor. Researchers will also track how long the tumor stays controlled and monitor side effects. This is an early-phase trial, so the focus is on safety and initial effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Medical University, Nanfang Hospital, Department of Neurosurgery
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.